WM is a distinct low-grade lymphoproliferative disorder. When therapy is indicated, alkylating agents, nucleoside analogs, and rituximab are reasonable choices. Several factors, including the presence of cytopenias, need for rapid disease control, candidacy for ASCT, age, and comorbidities, should be taken into consideration when choosing the most appropriate primary treatment.
Meletios A Dimopoulos, Morie A. Gertz, Efstathios Kastritis, Ramón García‐Sánz, Eva Kimby, Véronique Leblond, Jean-Paul Fermand, Giampaolo Merlini, Pierre Morel, Enrica Morra, Enrique M. Ocio, Roger G. Owen, Irene M. Ghobrial, John F. Seymour, Robert A. Kyle, Steven P. Treon
Meletios A Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García‐Sánz, Nikhil C. Munshi, Kenneth C. Anderson, Evangelos Terpos, Irene M. Ghobrial, Pierre Morel, David G. Maloney, Mathias Rummel, Véronique Leblond, Ranjana H. Advani, Morie A. Gertz, Charalampia Kyriakou, Sheeba K. Thomas, Bart Barlogie, Stephanie A. Gregory, Eva Kimby,
Meletios A Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, Xavier Leleu, Nikhil C. Munshi, Kenneth C. Anderson, Irene M. Ghobrial, David G. Maloney, Ranjana H. Advani, Morie A. Gertz, Sheeba K. Thomas, Steven P. Treon
Discussion(0)
No comments yet. Be the first to comment.